Medical & Health News Weekly

Marine omega fatty acids don’t prevent cardiovascular events or cancer  link

Vitamin D supplementation doesn’t prevent cardiovascular disease or cancer  link

(But just to confuse the issue, some headlines putting a positive spin using less significant secondary outcomes  on Vit D and Fish oils!)

Cholesterol 2018 guidelines made simple (!)  link

Juul to stop selling most flavoured e-cigarettes link

Intraaortic Balloon Pump has no effect on mortality in a six year follow up in myocardial infarction with cardiogenic shock  link

US recommendations for screening all over age 18 for unhealthy alcohol use, including pregnant, and offer brief behavioural counselling  link

FDA warns on intrathecal (spinal) implanted pain pumps prone to pump failures, unapproved drugs or dosing errors  link

SGLT2 Inhibitors in diabetes appear to have beneficial effects on cardiac failure hospitalizations and progression of renal disease link

 

Cannabinoids for Pain

The British Pain Society adds a rational voice to the debate and hype re cannabis and cannabinoids for pain. It confirms what studies and meta-analyses have generally found, that the evidence base for effectiveness is weak. Concerns are expressed for potential side effects especially in terms of misuse, and effects on cognition and mental health (experts have consistently warned on the dangers in teenagers and use during pregnancy).

The Society feels that there is no evidence to support routine use in pain management but acknowledges their use when other modalities fail, and provides strict advice on monitoring and supporting such patients, with a plan to withdraw them when shown ineffective.

link

 

Safe Use Of High-Flow Nasal Oxygen (HFNO)

The Anesthesia Patient Safety Foundation provide an excellent overview of the popular and expanding use of High Flow Nasal Oxygen (HFNO), devices which are in many cases supplanting BIPAP, and  used to provide apneic ventilation during intubation, as well as post extubation and weaning from ventilation. This review also adds some caution, in particular the danger of fire, and contraindications.

link

 

Post-Dural Puncture Headache

A small study based on chart reviews limits the findings of this study which should be tested in future controlled studies. Nonetheless an interesting approach to postdural puncture headache was performed in the form of a topical sphenopalatine ganglion block and compared to the standard epidural blood patch. This ganglion block is being tested for migraine and other headaches but remains investigational.  (These topical blocks are usually described as simply placing local anesthetic soaked swabs along the floor of the nose until reaching and stopping at the nasopharynx and left there for 10mins or so, more recently with syringes attached to nasal catheter).

These authors found a faster headache resolution at 30 and 60 minutes with sphenopalatine block.

link

 

Graduated Compression Stockings and DVT

The Cochrane group weigh in on the common thromboembolism deterrent (TED), or graduated compression  stockings (GCS).

The evidence is supportive in surgical patients, not so clear in the medical setting.

“There is high‐quality evidence that GCS are effective in reducing the risk of DVT in hospitalised patients who have undergone general and orthopaedic surgery, with or without other methods of background thromboprophylaxis, where clinically appropriate. There is moderate‐quality evidence that GCS probably reduce the risk of proximal DVT, and low‐quality evidence that GCS may reduce the risk of PE. However, there remains a paucity of evidence to assess the effectiveness of GCS in diminishing the risk of DVT in medical patients”.

link

 

Mental Health after Major Trauma

A retrospective analysis in Ontario showed that survivors of major trauma are at a higher risk of developing mental health conditions or death by suicide in the years after their injury. Thise with pre-existing mental health disorders or who are recovering from a self-inflicted injury are at particularly high risk.

This study adds to the huge developing body of evidence of health issues after critical illness – mental, PTSD, neurocognitive, other health issues.

cmaj link

 

Hydroxyethyl Starch Discontinuance and CABG Outcome

This study reflects the shift away from colloids, in particular Hydroxyethyl Starch (HES), due to its association with adverse outcomes particularly in sepsis and renal dysfunction. Its use during surgery has persisted somewhat, with evidence of improved or no different outcomes using HES in abdominal surgery, not necessarily translatable to cardiac or critical care settings.

While suffering from retrospective limitations, this study showed that “for patients undergoing CABG on CPB, disinvestment in HES was associated with a reduced length of hospital stay and reduced blood product transfusion, without measurable change in death, renal failure, or dialysis rate. This association suggests that the continued use of HES in the cardiac surgical setting should be carefully reconsidered”.

Cost savings is another advantage, and many would advocate removing HES from anesthesia carts, suggested in a correspondence in the same journal (CJA)

link

 

Crystalloids, Colloids and Renal / Disability Outcome

Colloids have been out of fashion due to evidence of increased renal injury and mortality in the critically ill. However, some studies have failed to demonstrate harm in surgical patients.

This 1 year follow up study shows that in patients undergoing major open abdominal surgery, “there was no evidence of a statistically significant difference in long-term renal function between a balanced hydroxyethyl starch and a balanced crystalloid solution used as part of intraoperative goal-directed fluid therapy, although there was only limited power to rule out a clinically significant difference. However, disability-free survival was significantly higher in the colloid than in the crystalloid group”.

The study was fairly small, and baseline WHODAS (disability) scores were not available, and the study may not be applicable to those with pre-existing renal impairment. Goal-directed pulse contour analysis was used to guide fluid administration, not universally available. Nonetheless, the eternal crystalloid-colloid debate continues!

link

 

Perioperative management of direct oral anticoagulants (DOACS) in cardiac surgery

An international consensus on managing new oral anticoagulants in patients having cardiac surgery provides pertinent information that will enlighten their use outside cardiac surgery also.

Measurement of DOACS may be useful in emergencies or uncertainty, or in significant renal or hepatic dysfunction; however, such measurement as well as routine coagulation testing is not recommended. Greater caution is also needed in the elderly. Dabigatran is particularly dependent on renal function.

Normal prothrombin time or activated partial thromboplastin time results exclude excess levels of dabigatran, rivaroxaban and edoxaban, but not apixaban. Normal thrombin time precludes significant dabigatran plasma levels, and the aPTT shows some correlation here also – for precise measurements, the diluted thrombin time (dTT), the ecarin clotting time or the ecarin chromogenic assay may be used. For the precise measurement of drug concentrations of all FXa inhibitors, chromogenic and calibrated anti‐FXa tests are recommended.

Reversal agents: for dabigatran, idarucizumab is available; for the FXa inhibitors, andexanet alpha has been approved in the US, and ciraparantag is currently under investigation. Ultrafiltration and Hemodialysis are also discussed for Dabigatran, and non-specific approaches of varying efficacy include prothrombin complex concentrate, fibrinogen concentrate, tranexamic acid and/or factor VIIa.

In general, withholding for 2 days is appropriate. For Dabigatran, this may need 3-5 days depending on renal function. Resumption at therapeutic doses is recommended after 2-3 days and after removal of chest drains. (In the non-cardiac surgery setting, resumption may be sooner depending on bleeding risk). Prophylactic doses may be needed sooner after surgery for thromboembolic prophylaxis. Bridging agents are not recommended for interruptions less than 4 days, as increased bleeding without lower thromboembolism is reported. Individualized approaches may be needed based on CHA2DS2‐VASc Score and bleeding risk.

From an anesthesia perspective, neuraxial anesthesia performance should be equated with high bleeding risk and longer interruption may be the preferred – the ASRA provides one such set of guidelines.

full text link